Evidence map›Paper›PMID 38852743›Full record

ReviewJournal of the American Academy of Dermatology2025

Dermatologic fungal neglected tropical diseases-Part I. Epidemiology and clinical features.

Kaya L Curtis, Jeremy A W Gold, Jana M Ritter, Theodore Rosen, Daniel Wagner C L Santos, Dallas J Smith, Shari R Lipner

Abstract readReview
In one paragraph

Review in Journal of the American Academy of Dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kaya L CurtisWeill Cornell Medical College, New York, New York.
Jeremy A W GoldCenters for Disease Control and Prevention, Mycotic Diseases Branch, Atlanta, Georgia.
Jana M RitterCenters for Disease Control and Prevention, Infectious Disease Pathology Branch, Atlanta, Georgia.
Theodore RosenDepartment of Dermatology, Baylor College of Medicine, Houston, Texas.
Daniel Wagner C L SantosHospital Universitário Presidente Dutra, HUPD - Ebserh, Federal University of Maranhão, São Luís, MA, Brazil; Instituto D'Or de Presquisa e Ensino, IDOR, Rede D'Or, São Luís, MA, Brazil.
Dallas J SmithCenters for Disease Control and Prevention, Mycotic Diseases Branch, Atlanta, Georgia.
Shari R LipnerDepartment of Dermatology, Weill Cornell Medicine, New York, New York. Electronic address: shl9032@med.cornell.edu.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

In this part 1 of a 2-part continuing medical education series, the epidemiology, clinical features, and diagnostic methods for fungal skin neglected tropical diseases (NTDs), which include eumycetoma, chromoblastomycosis, paracoccidioidomycosis, sporotrichosis, emergomycosis, talaromycosis, and lobomycosis, are reviewed. These infections, several of which are officially designated as NTDs by the World Health Organization, cause substantial morbidity and stigma worldwide and are receiving increased attention due to the potential for climate change-related geographic expansion. Domestic incidence may be increasing in the setting of global travel and immunosuppression. United States dermatologists may play a central role in early detection and initiation of appropriate treatment, leading to decreased morbidity and mortality.

Indexed as

DermatomycosesNeglected DiseasesHumansIncidencechromoblastomycosisdiagnosticsemergomycosisendemic mycosesepidemiologyeumycetomafungal infectionsimplantation mycoseslobomycosisneglected tropical diseasesparacoccidioidomycosissporotrichosissystemic mycosestalaromycosis

Identifiers

PMID38852743
PMCPMC11970523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.